Please login to the form below

Not currently logged in
Email:
Password:

AZ hit by $445m charge

AstraZeneca will face impairment charges of $445m following the discontinued development of motavizumab for the prevention of RSV

AstraZeneca (AZ) will face impairment charges of $445m following the discontinued development of motavizumab for the prevention of serious respiratory syncytial virus (RSV) disease.

The charge, which relates to a reduction in the value of a company based on poor previous estimates regarding intangible assets, will occur in the financial results of the fourth quarter of 2010.

AZ has also requested withdrawal of the biological licence application (BLA) currently pending with the US Food and Drug Administration (FDA).

The original BLA for motavizumab was filed in January 2008, with the first complete response letter (CRL) sent in November 2008.

The investigational monoclonal antibody was then reviewed by the FDA's Antiviral Drugs Advisory Committee in June 2010, with concerns over some of the drug's side effects and a request for additional clinical data.

AZ then decided to discontinue motavizumab for the prevention of RSV, which causes infection to the lungs and breathing passages, though the drug remains in development for other types of RSV treatment.

This is the second recent setback for AZ, following the FDA's decision to deny approval for Brilinta (ticagrelor), a potential new drug for acute coronary syndrome.

The agency asked for additional analyses of trial data, with concerns that patients were more likely to experience heart problems with Brilinta over other treatments.

21st December 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

Star’s a full service resourcing house and for almost 12 years we’ve recruited the best people for pharma, medical devices...

Latest intelligence

Growing influence of pharmacists in the sale of Rx and OTC medicines
Find out how the changes within pharmacy have affected their influence over the sales of RX and OTC medicines in this whitepaper....
Drivers of 2014′s Soaring Drug Approvals
The FDA & EMA approved a chart-topping number of new drugs in 2014. Read more in our White Paper about the responsibility this growing approval success will put on future...
Russian innovation at the crossroads
Despite improvements, investors face rising risks...